article thumbnail

Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

Drug Discovery Today

Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

Vaccine 100
article thumbnail

Not all neoantigens are created equal

Drug Target Review

During the process of transformation from a normal cell into a cancer cell, a cell acquires a series of changes, or mutations, in its DNA. But DNA mutations can also result in changes to the proteins that are displayed on the surface of the cancer cell.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The science of ageing and restoring healthspan

Drug Target Review

Modifications to the epigenome, such as DNA hypermethylation, modify the expression of genes by increasing or decreasing their expression without altering the genes themselves. One way we are doing this at Life Biosciences is through partial epigenetic reprogramming. The epigenome drifts with age, leading to dysregulated gene expression.

Science 145
article thumbnail

Unveiling neoantigen-directed cancer treatment

Drug Target Review

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105
article thumbnail

T-cell receptors offer window to the cell for a new class of cancer therapeutics

Drug Target Review

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. In previous decades, isolation, sequencing and characterisation of DNA encoding a specific TCR was laborious and technically challenging. References Robinson R, McMurran C, McCully M, Cole D.

article thumbnail

Women in Stem with Dr Christine Schuberth-Wagner

Drug Target Review

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105
article thumbnail

Navigating the challenges and opportunities of AI in drug development and personalised medicine

Drug Target Review

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. Cavlan explains that “they are brilliant at developing and bringing new drugs to market.”